Log Out
 

Continuing our coverage of CONy 2019, we are reporting on two debates supported by Teva in the field of diagnosis and treatment of migraine.

The first debate, hosted by Dr. Christian Lampl (Headache Medical Centre Linz, Austria), explored the question whether monoclonal antibodies (mAbs) to calcitonin gene-related peptide (CGRP) will become first-line treatment not only for migraine, but also for episodic cluster headache. Dr. Lars Edvinsson (Lund University Hospital, Sweden)—who discovered CGRP and established its link to the trigeminovascular system implicated in migraine in the early 1980’s—supported the view that anti-CGRP mAbs had the potential to become first-line agents in the treatment of both of these headache types. Dr. Edvinsson emphasized the fact that most traditional prophylactic drugs—e.g. beta-blockers, anti-de

References

  1. Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478-88.

  2. Hou M, Xing H, Cai Y, Li B, Wang X, Li P, Hu X, Chen J. The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis. J Headache Pain. 2017;18(1):42. doi: 10.1186/s10194-017-0750-1.

  3. Dodick DW, Turkel CC, DeGryse RE, et al. Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example. J Pain. 2015;16(2):164-75.